CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 62 enrolled
Drug / intervention
SC anti-TNFother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01521884
NCT01521884N/ACompleted
CompareCT.gov

Longitudinal Changes In Fatigue And Health Status (aims2) In Ra Patients Treated With Sc Anti-tnf-alpha Therapy

Pfizer·observational·Posted Jan 31, 2012·Updated Feb 19, 2015

In Brief

An observational study evaluating SC anti-TNF for Rheumatoid Arthritis. Completed, enrolled 62 participants across 1 site.

Detailed Summary

People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 31, 2012
Enrollment StartNov 1, 2010
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.4 years ago

Interventions

SC anti-TNFother

SC anti-TNF